Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid [2]

British Journal of Haematology

Volumn 125, Issue 1, 2004, Pages 91-92

  Perifanis, Vasilios ^a   Vyzantiadis, Timos ^a   Vakalopoulou, Sofia ^a   Tziomalos, Konstantinos ^a   Garypidou, Vasilia ^a   Athanassiou Metaxa, Miranta ^b   Harsoulis, Fedon ^a  

^a Ippokration Hospital Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Insulin like growth factor 1; Osteoporosis; Osteoprotegerin; Thalassaemia; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; SOMATOMEDIN C; VITAMIN D; ZOLEDRONIC ACID;

ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DENSITY; BONE MINERAL; CALCIUM INTAKE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LETTER; LUMBAR SPINE; MALE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ADULT; BETA-THALASSEMIA; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INSULIN-LIKE GROWTH FACTOR I; MALE; OSTEOPOROSIS;

EID: 1842505706     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04871.x     Document Type: Letter

References (6)

1. Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W.J., Lacey, D.L. & Riggs, B.L. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. Journal of Clinical Investigation, 111, 1221-1230.
2. Haynes, D.R., Crotti, T.N., Loric, M., Bain, G.I., Atkins, G.J. & Findlay, D.M. (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology, 40, 623-630.
3. Mahachoklertwattana, P., Sirikulchayanonta, V., Chuansumrit, A., Karnsombat, P., Choubtum, L., Sriphrapradang, A., Domrongkitchaiporn, S., Sirisriro, R. & Rajatanavin, R. (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. The Journal of Clinical Endocrinology and Metabolism, 88, 3966-3972.
4. Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.P., Kaufman, J.M., Jaeger, P., Body, J.J., Brandi, M.L., Broell, J., Di Micco, R., Genazzani, A.R., Felsenberg, D., Happ, J., Hooper, M.J., Ittner, J., Leb, G., Mallmin, H., Murray, T., Ortolani, S., Rubinacci, A., Sääf, A., Samsioe, G., Verbruggen, L. & Meunier, P.J. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. The New England Journal of Medicine, 346, 653-661.
5. Viereck, V., Ernons, G., Lauck, V., Frosch, K.H., Blaschke, S., Grundker, C. & Hofbauer, L.C. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochemical and Biophysical Research Communications, 291, 680-686.
6. Voskaridou, E., Terpos, E., Spina, G., Palermos, J., Rahemtulla, A., Loutradi, A. & Loukopoulos, D. (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. British Journal of Haematology, 123, 730-737.